Santarus Licenses Novel Type 2 Diabetes Drug CYCLOSET

Links shared publicly online about this topic.

883
total visits

Santarus Licenses Novel Type 2 Diabetes Drug CYCLOSET

Santarus, Inc. (NASDAQ: SNTS), S2 Therapeutics, Inc. and VeroScience LLC today announced that they have entered into a distribution and license agreement granting Santarus exclusive rights to manu

View full resource at medicalnewstoday.com

Tags: Diabetes, Diabetes Type 2 Medication, Diabetes Medication, Type 2 Diabetes, Drug

Most Recently Shared on September 10, 2010 at 5:00 pm By:

MNT Diabetes News

Santarus Licenses Novel Type 2 Diabetes Drug CYCLOSET http://mnt.to/3JxK #diabetes

2 years ago...

Retweet

Favorite

Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET | Business Wire

businesswire.com — “Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced the commercial U.S. launch of CYCLOSET® (bromocriptine mesyl” View full resource at businesswire.com

Most Recently Shared on November 16, 2010 at 1:57 pm By:

Hope Warshaw Dietitian and Nutritionist

New diabetes drug enters market: Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET http://bit.ly/cjSjV4

1 year ago...

Retweet

Favorite

Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET | Diabetes | Type 2 Diabetes | Diabetes Mellitus | Keyvive.com

keyvive.com — “Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET | Diabetes | Type 2 Diabetes | Diabetes Mellitus | Keyvive.com” View full resource at keyvive.com